A PYMNTS Company

Thirty-three states settle with Aventis and Ferring for delayed generic

By  |  January 31, 2012

Thirty-three states have reached a settlement with Aventis and Ferring, two pharmaceutical companies, for delaying the entry of the generic for DDAVP (desmopressin). Barr Laboratories, the manufacturer of the generic, allegedly had its sales delayed because of materially misleading statements Aventis and Ferring made to the U.S. Patent Office.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Source: LegalNewsline

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

     

    Related content: Whistling Past the Graveyard: The Problem with the Per Se Legality Treatment of Pay-For-Delay Settlements (Michael Kades, U.S. Federal Trade Commission)